Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S3050597626000606?dgcid=rss_sd_all
Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S3050597626000606?dgcid=rss_sd_all
“Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.” Blood Immunology & Cellular Therapy.
@article{article38112,
title = {Epcoritamab and glofitamab as bridging therapy prior to CAR T-cell therapy in relapsed/refractory large B-cell lymphoma},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S3050597626000606?dgcid=rss_sd_all}
}